Literature DB >> 17667197

Prevalence of depression diagnoses and use of antidepressant medications by veterans with spinal cord injury.

Bridget M Smith1, Frances M Weaver, Philip M Ullrich.   

Abstract

OBJECTIVES: The objectives of this study were to examine the prevalence of depression diagnoses among veterans with spinal cord injuries and disabilities (SCI&D) for a 3-yr period, and to characterize patterns of antidepressant medication use in this population.
DESIGN: This study was a retrospective analysis of clinical and administrative data. The sample consisted of 3678 veterans with SCI&D who had received any health care at a Department of Veterans Affairs facility between fiscal years 1999 and 2001, a depression diagnosis, and complete data. Logistic regression analysis was used to examine associations between patient characteristics, antidepressant types, and prescription patterns.
RESULTS: Approximately 22% of veterans with SCI&D received a diagnosis of depression during at least one encounter with a healthcare provider. Of those diagnosed, 72% received antidepressant prescriptions. However, a large percentage (67%) did not continue antidepressant use for 6 mos. Patients started on a selective serotonin reuptake inhibitor were more likely to have at least 6 mos of continuous use than patients started on other, newer antidepressants.
CONCLUSIONS: Many veterans with SCI&D may not be receiving adequate treatment for depression. Veterans with SCI&D should be aggressively screened and treated for depression, and further research is necessary to determine which treatments for depression are most effective for persons with SCI&D.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17667197     DOI: 10.1097/PHM.0b013e318114cb6d

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  7 in total

1.  Divergent modulation of clinical measures of volitional and reflexive motor behaviors following serotonergic medications in human incomplete spinal cord injury.

Authors:  Christopher K Thompson; T George Hornby
Journal:  J Neurotrauma       Date:  2013-04-03       Impact factor: 5.269

2.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

3.  Depression, healthcare utilization, and comorbid psychiatric disorders after spinal cord injury.

Authors:  Philip M Ullrich; Bridget M Smith; Frederic C Blow; Marcia Valenstein; Frances M Weaver
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

4.  Mental disorder prevalence among U.S. Department of Veterans Affairs outpatients with spinal cord injuries.

Authors:  Scott D McDonald; Melody N Mickens; Lisa D Goldberg-Looney; Brian J Mutchler; Michael S Ellwood; Teodoro A Castillo
Journal:  J Spinal Cord Med       Date:  2017-03-13       Impact factor: 1.985

5.  Depressive mood in individuals with spinal cord injury (SCI) living in Greece.

Authors:  Ioannis-Alexandros Tzanos; Andreas Mavrogenis; Konstantina Gioti; Panagiotis Papagelopoulos; Elias Panagiotopoulos
Journal:  Spinal Cord       Date:  2018-03-26       Impact factor: 2.772

6.  Using Inferred Mobility Status to Estimate the Time to Major Depressive Disorder Diagnosis Post-Spinal Cord Injury.

Authors:  Catherine J VanDerwerker; Chris M Gregory; Kit N Simpson
Journal:  Arch Phys Med Rehabil       Date:  2019-12-28       Impact factor: 3.966

7.  Development of Emotional Well-Being indicators to advance the quality of spinal cord injury rehabilitation: SCI-High Project.

Authors:  Sander L Hitzig; Rebecca Titman; Steven Orenczuk; Teren Clarke; Heather Flett; Vanessa K Noonan; Patricia Bain; Sandra Mills; Farnoosh Farahani; Matheus Joner Wiest; Gaya Jeyathevan; S Mohammad Alavinia; B Catharine Craven
Journal:  J Spinal Cord Med       Date:  2019-10       Impact factor: 1.985

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.